Medical Science Liaison; UK

Overview

About Summit Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s Team Is Inspired To Touch And Help Change Lives Through Summit’s Clinical Studies In The Field Of Oncology. Summit Has Multiple Global Phase 3 Clinical Studies, Including:

Non-small Cell Lung Cancer (NSCLC)

• HARMONi:
  Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
• HARMONi-3:
  Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
• HARMONi-7:
  Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

• HARMONi-GI3:
  Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview Of Role: Summit Therapeutics is seeking an experienced and dynamic Medical Affairs Director to lead the development and implementation of medical strategies for ivonescimab targeting different solid tumor cancers. This role will involve close collaboration with cross-functional teams, including clinical development, regulatory affairs, and commercial operations, to support the investigation and eventual commercialization of ivonescimab in different indications. The ideal candidate is able to demonstrate effective planning and execution of medical affairs strategies leading to a successful development or adoption of an oncology therapy, as well as ability to analyze, summarize, and deliver complex scientific data to a multitude of audiences.

Overview Of Role: The Medical Science Liaison (MSL) is a field-based scientific expert specializing in Immuno-Oncology and related treatment options. They play a strategic role in supporting Summit’s scientific and business objectives throughout the oncology product lifecycle. MSLs act as the primary scientific communicators for Summit within their designated regions, engaging with healthcare professionals and supporting clinical site activities.

Combining strong business acumen, clinical expertise, and market awareness, MSLs serve as vital conduits of information to various stakeholders within Summit. Depending on therapeutic needs and product life cycles, their responsibilities may include clinical development and pipeline support.

• Develop, execute, and maintain high-impact territory plans, including HCP and Investigator engagement plans, aligned with therapeutic area medical and scientific objectives, focusing on quality
• Identify, gain access to, and develop professional, customer-centric relationships with external experts in Immuno-Oncology within the assigned geography
• Provide education on disease state, therapeutic landscape, and Summit’s products across the product lifecycle to healthcare providers and researchers.
• Support clinical development, clinical operations, and research initiatives, including site evaluation and identification, recruitment, investigator meetings, external expert identification,…